News | October 31, 2011

Lantheus Awarded Supplier Agreement with Premier for Radiopharmaceutical Products

October 31, 2011 –Lantheus Medical announced it has been awarded a three-year supplier contract with Premier Purchasing Partners, the group purchasing unit of the Premier healthcare alliance, for its radiopharmaceutical imaging agents.

Effective Jan. 1, 2012 through Dec. 31, 2014, the new radiopharmaceutical products agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Cardiolite (kit for the preparation of Technetium Tc99m Sestamibi for injection), Gallium 67 (Gallium Citrate Ga67 injections), Neurolite (kit for the preparation of Technetium Tc99m Bicisate for Injection), TechneLite (Technetium Tc99m generator), 201 Thallium (Thallous Chloride Tl201 Injection) and Xenon 133 (Xenon Xe 133 gas).

Lantheus’ radiopharmaceutical products will be offered through a specially negotiated contract to more than 2,500 hospitals nationwide and 76,000-plus healthcare sites. The contract was awarded after a competitive bidding process that examined multiple factors, including pricing and clinical experience with the diagnostic imaging agents, as well as Lantheus’ support of the products.

Please visit www.lantheus.com

Related Content

CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) — the voice of the radionuclide, radiopharmaceutical...
Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 26, 2018 | Dave Fornell
February 8, 2018 — The U.S.
ARTMS Products Inc. and GE Healthcare Team Up to Expand Cyclotron-Produced Radioisotopes
News | Radiopharmaceuticals and Tracers | August 30, 2017
ARTMS Products Inc. signed a strategic partnership with GE Healthcare around ARTMS’ proprietary QUANTM99 Irradiation...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a...
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the development of a new...
University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes
News | Radiopharmaceuticals and Tracers | April 13, 2017
The University of Missouri Research Reactor (MURR) and its partners Nordion and General Atomics (GA), announced in...
IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Become Curium
News | Radiopharmaceuticals and Tracers | April 11, 2017
April 11, 2017 — IBA Molecular announced that it has merged with previous acquisition Mallinckrodt...
GE Healthcare, HealthTrust, supply agreement, nuclear imaging, radiopharmaceuticals
News | Radiopharmaceuticals and Tracers | April 05, 2017
April 5, 2017 — GE Healthcare has signed an agreement with HealthTrust, a group purchasing organization headquartered
Nuclear cardiology, nuclear imaging, radiotracer production, automated radiosynthesis module, myocardial perfusion imaging
Feature | Radiopharmaceuticals and Tracers | March 01, 2017 | Anamika Kumari
Huge portions of the globally produced radiotracers find their origin within geographically centralized, commercial r
News | Radiopharmaceuticals and Tracers | January 17, 2017
NorthStar Medical Technologies LLC has received additional matching funds from the U.S. Department of Energy’s National...
Overlay Init